<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04663230</url>
  </required_header>
  <id_info>
    <org_study_id>AZ 12320</org_study_id>
    <nct_id>NCT04663230</nct_id>
  </id_info>
  <brief_title>Right Atrial Fibrosis in Pulmonary Hypertension</brief_title>
  <acronym>RAFE-PH</acronym>
  <official_title>Right Atrial Fibrosis in Pulmonary Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Giessen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Giessen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aim to assess right atrial (RA) remodeling, in terms of RA fibrosis, in pulmonary&#xD;
      arterial hypertension and chronic thromboembolic pulmonary hypertension patients. This will&#xD;
      be investigated in detail with in-depth cardiac magnet resonance imaging (CMRI). A cohort&#xD;
      with exclusion of pulmonary hypertension which underwent CMRI due to dyspnoe of unkown reason&#xD;
      will be the control group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Right atrial (RA) function consists of a reservoir, conduit, and active contractile function&#xD;
      and can serve as a tool for the evaluation of the severity of RV dysfunction and prognosis in&#xD;
      pulmonary hypertension according to recent data. In-depth evaluation of phasic RA function&#xD;
      was previously undertaken either by echocardiographic speckle tracking or by cardiac magnetic&#xD;
      resonance (CMR) imaging-derived feature tracking. However, it is currently unknown if right&#xD;
      atrial remodeling is present.&#xD;
&#xD;
      As described for left atrial fibrosis, the presence and extent of atrial fibrosis can be&#xD;
      quantified using CMR late gadolinium enhancement. The protocol for the assessment of left&#xD;
      atrial fibrosis will be used and adapted to the RA. Patients will undergo 3-dimensional late&#xD;
      gadolinium enhancement CMRI along with a contrast-enhanced magnetic resonance angiography and&#xD;
      cine imaging in order to define the anatomy of the RA and the superior and inferior vein.&#xD;
      High-resolution late gadolinium enhancement images of the RA will be acquired 15 to 30 min&#xD;
      after gadolinium-based contrast agents administration using a 3-dimensional&#xD;
      inversion-recovery prepared, respiration navigated, and electrocardiogram triggered&#xD;
      gradient-echo pulse sequence with fat saturation. Following acquisition of the scans, the&#xD;
      endocardial borders of the RA will be defined in each slice by manual tracing. After manual&#xD;
      adjustment of the epicardial RA surface, the quantification of fibrosis based on the relative&#xD;
      intensity (signal intensity) of late gadolinium enhancement will be performed. Finally, a&#xD;
      3-dimensional model of the RA will be rendered with the maximum enhancement intensities being&#xD;
      projected on the model surface.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2021</start_date>
  <completion_date type="Anticipated">November 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>atrial fibrosis</measure>
    <time_frame>1 day</time_frame>
    <description>right atrial late gadolinium enhancement in % and cm2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of right atrial fibrosis with functional and exercise capacity</measure>
    <time_frame>1 day</time_frame>
    <description>right atrial late gadolinium enhancement in % and cm2 correlated with 6minute walking distance in m or peak oxygen uptake in ml/min/kg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of right atrial fibrosis with remodeling of the right atrium, backflow and systemic congestion</measure>
    <time_frame>1 day</time_frame>
    <description>right atrial late gadolinium enhancement in % and cm2 correlated with right atrial size (volume and cm2) and inferior vena cava diameter in cm2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of right atrial fibrosis with pulmonary hemodynamics</measure>
    <time_frame>1 day</time_frame>
    <description>right atrial late gadolinium enhancement in % and cm2 correlated with mean right atrial pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of right atrial fibrosis with load-independent right ventricular function assessed by pressure-volume loop catheterization</measure>
    <time_frame>1 day</time_frame>
    <description>right atrial late gadolinium enhancement in % and cm2 correlated with end-systolic to arterial elastance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of right atrial fibrosis with biomarkers</measure>
    <time_frame>1 day</time_frame>
    <description>right atrial late gadolinium enhancement in % and cm2 correlated with B-type natriuretic peptide in pg/ml</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prognostic relevance of right atrial fibrosis</measure>
    <time_frame>1 day</time_frame>
    <description>right atrial late gadolinium enhancement in % and cm2 as a predictor of clinical worsening or death</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <condition>Chronic Thromboembolic Pulmonary Hypertension</condition>
  <condition>Pulmonary Arterial Hypertension</condition>
  <arm_group>
    <arm_group_label>Pulmonary arterial hypertension</arm_group_label>
    <description>Patients with mean pulmonary arterial pressure above 25 mmHg, and a pulmonary capillary wedge pressure below 15 mmHg classified into group 1 of the clinical classification of pulmonary hypertension.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chronic thromboembolic pulmonary hypertension</arm_group_label>
    <description>Patients with mean pulmonary arterial pressure above 25 mmHg, and a pulmonary capillary wedge pressure below 15 mmHg with a history of pulmonary embolism, classified into group 4 of the clinical classification of pulmonary hypertension.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Patients with invasive exclusion of pulmonary hypertension (mean pulmonary arterial pressure below 25 mmHg) undergoing diagnostic CMRI due to the evaluation of dyspnoea.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>cardiac magnetic resonance imaging</intervention_name>
    <description>right atrial late gadolinium enhancement in % and cm2</description>
    <arm_group_label>Chronic thromboembolic pulmonary hypertension</arm_group_label>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Pulmonary arterial hypertension</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        40 subjects with pulmonary arterial hypertension, group 1 and chronic thromboembolic&#xD;
        pulmonary hypertension, group 4; Patients with invasive exclusion of pulmonary hypertension&#xD;
        undergoing diagnostic right heart catheterisation due to dyspnoe will serve as control&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of pulmonary arterial hypertension, WHO group 1 or chronic&#xD;
             thromboembolic pulmonary hypertension, group 4&#xD;
&#xD;
          -  Invasive exclusion of pulmonary hypertension&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  planned right heart catheterization based on clinical grounds&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Other etiologic groups of pulmonary hypertension (WHO group 2, 3, 5)&#xD;
&#xD;
          -  Patients with congenital heart disease&#xD;
&#xD;
          -  Atrial septal defects&#xD;
&#xD;
          -  Clinical relevant left heart disease&#xD;
&#xD;
          -  Atrial fibrillation / Atrial flutter&#xD;
&#xD;
          -  Ablations of the right atrium&#xD;
&#xD;
          -  History of major cardiac surgery&#xD;
&#xD;
          -  Atrial occlude&#xD;
&#xD;
          -  Metallic implants&#xD;
&#xD;
          -  Pacemakers&#xD;
&#xD;
          -  Severe renal impairment (eGFR &lt; 30 ml/min)&#xD;
&#xD;
          -  Other severe disease with a life expectancy below 12 month&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Any known factor or disease that might interfere with treatment compliance, study&#xD;
             conduct, or interpretation of results&#xD;
&#xD;
          -  Intolerance to a contrast agent containing gadolinium&#xD;
&#xD;
          -  Inability to perform a cardiac magnetic resonance imaging (claustrophobia or similar)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richter Manuel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UKGM Giessen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richter Manuel, MD</last_name>
    <phone>+4964198556022</phone>
    <email>manuel.j.richter@innere.med.uni-giessen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kerckhoff-Klinik</name>
      <address>
        <city>Bad Nauheim</city>
        <state>Hesse</state>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richter Manuel, MD</last_name>
      <phone>+4964198556022</phone>
      <email>manuel.j.richter@innere.med.uni-giessen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Giessen</name>
      <address>
        <city>Gießen</city>
        <state>Hesse</state>
        <zip>35390</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Richter, MD</last_name>
      <phone>+4964198556022</phone>
      <email>manuel.j.richter@innere.med.uni-giessen.de</email>
    </contact>
    <investigator>
      <last_name>Khodr Tello, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 9, 2020</study_first_submitted>
  <study_first_submitted_qc>December 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2020</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Pulmonary Arterial Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Upon reasonable request</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

